Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 0.76 |
| ▸ | USP2 | O75604 | 1/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.46 |
| ▸ | TSHR | P16473 | 1/20 | 0.46 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.46 |
| ▸ | RECQL | P46063 | 1/20 | 0.46 |
| ▸ | GAA | P10253 | 3/20 | 0.44 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.44 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.41 |
| ▸ | HPGD | P15428 | 1/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.41 |
| ▸ | HTT | P42858 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26495871 | 0.83 | KMT2A (0.60) | KMT2AUSP2TSHRNPSR1MEN1 | |
| SCHEMBL29763021 | 0.81 | KMT2A (0.64) | KMT2AUSP2GAAPOLBMEN1 | |
| SCHEMBL30376120 | 0.79 | KMT2A (0.51) | KMT2AL3MBTL1 | |
| SCHEMBL24152939 | 0.74 | L3MBTL1 (0.49) | KMT2AL3MBTL1ALDH1A1 | |
| SCHEMBL30376243 | 0.74 | L3MBTL1 (0.49) | KMT2AL3MBTL1ALDH1A1 | |
| SCHEMBL15690501 | 0.71 | NAMPT (0.50) | KMT2AL3MBTL1TSHRGAAMEN1 | |
| SCHEMBL30464159 | 0.70 | KMT2A (0.68) | KMT2AUSP2TSHRGAAPOLB | |
| SCHEMBL17339938 | 0.68 | POLB (0.56) | KMT2AUSP2L3MBTL1TSHRPOLB | |
| SCHEMBL15691864 | 0.68 | NAMPT (0.47) | KMT2APOLBMEN1LMNA | |
| SCHEMBL29763070 | 0.68 | PKM (0.60) | KMT2AUSP2TSHRGAANPSR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11787780-B2 | Quaternary indazole glucocorticoid receptor antagonists | CORCEPT THERAPEUTICS INCORPORATED (US) | 2023-10-17 | — | — | US | disclosed |
| US-20230032612-A1 | QUATERNARY INDAZOLE GLUCOCORTICOID RECEPTOR ANTAGONISTS | CORCEPT THERAPEUTICS INCORPORATED | 2023-02-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11787780-B2 | Quaternary indazole glucocorticoid receptor antagonists | NR3C1, NR3C2, MC2R | KMT2A 3581/4885USP2 2858/4885L3MBTL1 4835/4885 |
| US-20230032612-A1 | QUATERNARY INDAZOLE GLUCOCORTICOID RECEPTOR ANTAGONISTS | NR3C1, NR3C2, MC2R | KMT2A 3581/4885USP2 2858/4885L3MBTL1 4835/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.